Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD33 CAR-NK Cells in Relapsed/Refractory AML
NCT02944162Phase 2Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-CD33 CAR-NK cells in acute myeloid leukemia (AML), sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse events attributed to the administration of the anti-CD33 CAR-NK cells at 1 year. Status: unknown.
02
Drugs
Anti-CD33 CAR-NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02944162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944162.